A Phase 3 interventional study of Lebrikizumab in Atopic Dermatitis and Eczema, sponsored by Almirall, S.A.. Completed at 33 sites in 3 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-07-17.
Sponsored by Almirall, S.A. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing lebrikizumab in Dermatitis, Atopic — 4 open to participants now, 7 under way, 4 of them phase 3. lebrikizumab · Dermatitis, Atopic.
Among the 24 studies testing lebrikizumab in Dermatitis, Atopic, this one is the 11th largest by enrollment, is one of 4 that started in 2023, is one of 17 in phase 3, and was the 17th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →4 of the 24 studies testing lebrikizumab in Dermatitis, Atopic are open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Argentina, Australia and 10 more countries
Ages 6 mo–18 yrs
Forefront Dermatology S.C · Sites in United States
Ages 12+
Almirall, S.A.
Ages 12+
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
lebrikizumab: first FDA approval 2024 (EBGLYSS), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 4 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 260 is above the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 252 across the 24 interventional studies. Of the 17 that completed or were terminated, 13 (76%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 24 have an industry lead sponsor. The 6 most frequent:
Almirall, S.A. is the lead sponsor of 66 studies on the registry; 9 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 7 (78%) have results posted.
Almirall, S.A. has 7 studies filed under Dermatitis, Atopic — fewer than ten, so there is no comparison to draw.
3 of the studies testing lebrikizumab in Dermatitis, Atopic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06526182Phase 3Almirall, S.A.A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis | 2027-04-25 |
| NCT06906497Johann E Gudjonsson MD PhDLebrikizumab in Moderate-to-severe Atopic Dermatitis | 2027-07 |
| NCT07856134Forefront Dermatology S.CAD Treatment Optimization With Ebglyss in Real-World Practice: A Multicenter Study of Patient-Centered Outcomes | 2027-08-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 24 studies testing lebrikizumab in Dermatitis, Atopic, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to evaluate the effectiveness of 24 weeks of lebrikizumab in improving disease severity, signs, and symptoms in adults and adolescents with moderate-to-severe atopic dermatitis (AD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Occurrence of the following types of infection within 3 months of Screening or develop any of these infections before Day 1/Baseline:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive loading doses of lebrikizumab 500 milligrams (mg) subcutaneous (SC) injection at Day 1 and Week 2 followed by lebrikizumab 250 mg SC injection, every two weeks (Q2W) from Week 4 to Week 16. At Week 16, the dosing frequency will be reduced to every 4 weeks (Q4W) and will receive lebrikizumab 250 mg SC injection for up to Week 24, last dose of study medication is administered at Week 20.
Biological: Lebrikizumab
Lebrikizumab solution for injection administered subcutaneously.
Percentage of Participants Who Achieved Eczema Area and Severity Index (EASI) Total Score Less Than or Equal to (<=) 7 at Week 24
The EASI is used to assess the severity and extent of AD; it is a composite index with total score ranging from 0 to 72, with higher values indicating more severe and extensive disease. The severity of erythema, induration/papulation, excoriation, and lichenification will be assessed by the Investigator or trained designee on a scale of 0 (absent) to 3 (severe) for each of the 4 body areas: head/neck, trunk, upper limbs, and lower limbs, with half points allowed. In addition, the extent of AD involvement in each of the 4 body areas will be assessed as a percentage by body area of head/neck, trunk, upper limbs, and lower limbs, and converted to a score of 0 (0%), 1 (0 to 9%), 2 (10 to 29%), 3 (30 to 49%), 4 (50 to 69%), 5 (70 to 89%) and 6 (90 to 100%). Percentage of participants who achieved EASI total \<= 7 at Week 24 was reported.
Time frame: At Week 24
Percentage of Participants Who Achieved EASI Total Score <=7, EASI <=5, and EASI <=3 by Visit
The EASI is used to assess the severity and extent of AD; it is a composite index with total score ranging from 0 to 72, with higher values indicating more severe and extensive disease. The severity of erythema, induration/papulation, excoriation, and lichenification will be assessed by the Investigator or trained designee on a scale of 0 (absent) to 3 (severe) for each of the 4 body areas: head/neck, trunk, upper limbs, and lower limbs, with half points allowed. In addition, the extent of AD involvement in each of the 4 body areas will be assessed as a percentage by body area of head/neck, trunk, upper limbs, and lower limbs, and converted to a score of 0 (0%), 1 (0 to 9%), 2 (10 to 29%), 3 (30 to 49%), 4 (50 to 69%), 5 (70 to 89%) and 6 (90 to 100%). Percentage of participants who achieved EASI Total Score \<=7, EASI \<=5, and EASI \<=3 at each visit was reported.
Time frame: At Weeks 2, 4, 16, and 24
Percentage of Participants Who Achieved EASI 75 and EASI 90 by Visit
The EASI is used to assess the severity and extent of AD; it is a composite index with scores ranging from 0 to 72, with higher values indicating more severe and or extensive disease. EASI 75 is defined as 75% reduction from baseline in the EASI score. EASI 90 is defined as 90% reduction from baseline in the EASI score. Percentage of participants who achieved EASI 75 and EASI 90 at each visit was reported.
Time frame: At Weeks 2, 4, 16 and 24
Percentage of Participants With an Investigator Global Assessment (IGA) Score of 0 or 1 and a Reduction Greater Than or Equal to (>=2) Points From Baseline by Visit
The IGA is an instrument used to globally rate the severity of the participant's AD. It is based on a 5-point scale ranging from 0 (clear), 1 (almost clear), 2 (mild), 3 (moderate) and 4 (severe), and a score is selected using descriptors that best describe the overall appearance of the lesions at a given time point. The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting (minimal, palpable induration and significant induration). Percentage of participants with an IGA Score of 0 or 1 and a reduction \>=2 points from baseline at each visit was reported.
Time frame: At Weeks 2, 4, 16 and 24
Percentage of Participants Who Achieved Scoring Atopic Dermatitis (SCORAD) 75 and SCORAD 90 by Visit
SCORAD is a validated clinical tool for assessing the extent and intensity of AD. There are 3 components: surface involvement, intensity part and subjective assessment. Surface involvement is assessed as proportion of involved surface area segment by segment by applying the rule of 9s. Intensity part of the SCORAD consists of 6 items: erythema, oedema, oozing/crusting, excoriation, lichenification, and dryness. Each item is graded as follows: none (0), mild (1), moderate (2), or severe (3) (for a maximum of 18 total points). Subjective assessment of itch and of sleeplessness is recorded for each symptom using a VAS, where 0 is no itch (or sleeplessness) and 10 is the worst imaginable itch (or sleeplessness), for maximum possible score of 20. The score ranges from 0 to 103, with higher values indicating a more extensive and/or severe condition. SCORAD 75 is defined as 75% reduction in SCORAD from baseline. SCORAD 90 is defined as 90% reduction in SCORAD from baseline.
Time frame: At Week 2, 4, 16 and 24
Percentage Change From Baseline in Modified Total Lesion Symptom Score (mTLSS) (Hands) From Baseline by Visit
mTLSS combines an evaluation of hand eczema lesions severity including 6 key signs (erythema, desquamation, lichenification/hyperkeratosis, vesiculae, oedema, fissures) and the intensity of pruritus and pain. The seven features of AD of the hands (erythema, scaling, lichenification/hyperkeratosis, vesiculation, oedema, fissures, pruritus/pain) form the composite scale of mTLSS' strength and each one of them scores from (0 = none, 1 = mild, 2 = moderate, and 3 = severe). The scores are summed, extending from a base estimation of 0 (no signs or symptoms) to the most extreme of 21 (more serious disease). Percentage change from baseline was calculated as: (\[Observed or imputed value at post-baseline time point (i.e. Visit) - Observed value at Baseline\]/Observed value at Baseline) \*100.
Time frame: Baseline, Week 2, 4, 16, and 24
Percentage of Participants With Pruritus Numerical Rating Scale (NRS) >=4 at Baseline Who Achieved >=4-Point Improvement in Pruritus NRS From Baseline by Visit
The Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity score over the past 24 hours, with 0 (No itch) to 10 (Worst itch imaginable). Assessments will be recorded by the participant using an eDiary. Percentage of participants with pruritus NRS \>=4 at baseline who achieved \>=4-Point improvement in pruritus NRS from baseline at each visit was reported
Time frame: At Weeks 2, 4, 16 and 24
Percentage of Participants Who Achieved Dermatology Life Quality Index (DLQI) 0-1 by Visit
The DLQI is a 10-item validated questionnaire completed by the participant or caregiver used to assess the impact of skin disease on the participant's QoL during the previous week. The 10 questions cover the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, and treatment. Each question is scored from 0=not at all, 1=a little, 2=a lot, and 3=very much, giving a total score ranging from 0 to 30. A high score is indicative of a poor QoL. DLQI scores indicates 0-1 (no effect on patient's life), 2-5 (small effect on patient's life), 6-10 (moderate effect on patient's life), 11-20 (very large effect on patient's life), 21-30 (extremely large effect on patient's life). Percentage of participants who achieved DLQI 0-1 at each visit was reported.
Time frame: At Weeks 2, 4, 16 and 24
Percentage of Participants With DLQI >=4 at Baseline Who Achieved >=4-Point Improvement in DLQI From Baseline by Visit
DLQI is a 10-item validated questionnaire completed by the participant or caregiver used to assess the impact of skin disease on the participant's QoL during the previous week. The 10 questions cover the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, and treatment. Each question is scored from 0=not at all, 1=a little, 2=a lot, and 3=very much, giving a total score ranging from 0 to 30. High score is indicative of a poor QoL. Percentage of participants with DLQI \>=4 at Baseline who achieved \>=4-Point improvement in DLQI from baseline at each visit was reported.
Time frame: At Weeks 2, 4, 16 and 24
Percentage of Participants Who Achieved Children Dermatology Life Quality Index (cDLQI) 0-1 by Visit
cDLQI is validated from adolescents younger than age of 16 years, which is based on a set of 10 questions different from those of the DLQI. The answers to the questions are generally scored on a 4-point scale from 0=not at all or question unanswered, 1=only a little, 2=quite a lot, 3=very much. cDLQI is calculated by summing the score of each question resulting in 0 to 30. Higher the score, the more impairment of the child's life is experienced. Percentage of participants who achieved cDLQI 0-1 at each visit was reported.
Time frame: At Weeks 2, 4, 16 and 24
Percentage of Participants With cDLQI >=6 at Baseline Who Achieved >=6-Point Improvement in cDLQI From Baseline by Visit
cDLQI is validated from adolescents younger than age of 16 years, which is based on a set of 10 questions different from those of the DLQI. The answers to the questions are generally scored on a 4-point scale from 0=not at all or question unanswered, 1=only a little, 2=quite a lot, 3=very much. cDLQI is calculated by summing the score of each question resulting in 0 to 30. Higher the score, the more impairment of the child's life is experienced. Percentage of participants with cDLQI \>=6 at baseline who achieved \>=6-Point improvement in cDLQI from baseline at each visit was reported.
Time frame: At Week 2, 4, 16 and 24
Percentage of Participants With a Sleep-Loss Scale of >=2 Points at Baseline Who Achieved at Least 2-point Reduction From Baseline by Visit
Sleep loss will be assessed by all participants using a patient-related outcome (PRO) instrument. Participants (and if applicable, with help of parents/caregiver if required) will rate their sleep on a 5-point Likert scale (with scores ranging from 0 \[not at all\] to 4 \[unable to sleep at all\]). Assessments will be recorded by the participant using an eDiary.The baseline Sleep-Loss Scale score will be determined based on the average of daily Sleep-Loss Scale scores during the 7 days immediately before the Day 1 or Baseline visit. Percentage of participants with a Sleep-Loss scale of \>=2 points at baseline who achieved at least 2-point reduction from baseline at each visit was reported.
Time frame: At Weeks 2, 4, 16 and 24
Percentage of Participants With Patient-Oriented Eczema Measure (POEM) >=4 at Baseline Who Achieved >=4-Point Improvement in POEM From Baseline by Visit
The POEM is a 7-item, validated questionnaire completed by the participant (and, if applicable, with help of parents/caregiver if required) to assess disease symptoms. Participants are asked to respond to questions on skin dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping. All answers carry equal weight, with a total possible score ranging from 0 to 28 (answers scored as: No days = 0; 1-2 days = 1; 3-4 days = 2; 5-6 days = 3; every day = 4. A high score is indicative of a poor quality of life. POEM responses are captured weekly using an eDiary. Percentage of participants with POEM \>=4 at baseline who achieved \>=4-Point improvement in POEM from baseline at each visit was reported.
Time frame: At Weeks 2, 4, 16 and 24
Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Related TEAEs, TEAEs Leading to Study Treatment Discontinuation, and Treatment-emergent Adverse Events of Special Interest (TEAESIs)
TEAEs are undesirable events that first occurred or worsened in severity after the date of first IMP injection in the study, and on or prior to the date of the last visit within the treatment period. An SAE are AE, which falls into any of the following categories: death, is life-threatening, requires in-patient hospitalisation or prolongs existing hospitalisation, persistent or significant disability or incapacity, congenital anomaly or birth defect, or any other medically important event that may jeopardise the participant or may require intervention to prevent one of the other above outcomes. Related TEAEs includes events considered related or possibly related to study treatment by the Investigator. The following treatment-emergent AEs are being designated as AESIs: conjunctivitis, herpes simplex or zoster infection and parasitic infections.
Time frame: Baseline up to follow-up (Week 28)
The study was conducted at 41 sites in Germany, Netherlands and the United Kingdom from 20 November 2023 to 25 June 2025.
| Milestone | Lebrikizumab |
|---|---|
| Started | 260 |
| Modified full analysis set (mfas) | 247 |
| Completed | 243 |
| Not completed | 17 |
| Withdrew: Adverse event | 5 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Physician decision | 2 |
| Withdrew: Protocol deviation | 4 |
| Withdrew: Withdrawal by subject | 5 |
The EASI is used to assess the severity and extent of AD; it is a composite index with total score ranging from 0 to 72, with higher values indicating more severe and extensive disease. The severity of erythema, induration/papulation, excoriation, and lichenification will be assessed by the Investigator or trained designee on a scale of 0 (absent) to 3 (severe) for each of the 4 body areas: head/neck, trunk, upper limbs, and lower limbs, with half points allowed. In addition, the extent of AD involvement in each of the 4 body areas will be assessed as a percentage by body area of head/neck, trunk, upper limbs, and lower limbs, and converted to a score of 0 (0%), 1 (0 to 9%), 2 (10 to 29%), 3 (30 to 49%), 4 (50 to 69%), 5 (70 to 89%) and 6 (90 to 100%). Percentage of participants who achieved EASI total \<= 7 at Week 24 was reported.
| Percentage of participants | Lebrikizumab |
|---|---|
| Percentage of Participants Who Achieved Eczema Area and Severity Index (EASI) Total Score Less Than or Equal to (<=) 7 at Week 24 | 74.7 (69.2 to 80.3) |
The EASI is used to assess the severity and extent of AD; it is a composite index with total score ranging from 0 to 72, with higher values indicating more severe and extensive disease. The severity of erythema, induration/papulation, excoriation, and lichenification will be assessed by the Investigator or trained designee on a scale of 0 (absent) to 3 (severe) for each of the 4 body areas: head/neck, trunk, upper limbs, and lower limbs, with half points allowed. In addition, the extent of AD involvement in each of the 4 body areas will be assessed as a percentage by body area of head/neck, trunk, upper limbs, and lower limbs, and converted to a score of 0 (0%), 1 (0 to 9%), 2 (10 to 29%), 3 (30 to 49%), 4 (50 to 69%), 5 (70 to 89%) and 6 (90 to 100%). Percentage of participants who achieved EASI Total Score \<=7, EASI \<=5, and EASI \<=3 at each visit was reported.
| Percentage of participants | Lebrikizumab |
|---|---|
| EASI Total Score <=7: At Week 2 | 13.4 (9.1 to 17.6) |
| EASI Total Score <=7: At Week 4 | 35.9 (29.9 to 41.9) |
| EASI Total Score <=7: At Week 16 | 70.6 (64.7 to 76.4) |
| EASI Total Score <=5: At Week 2 | 8.1 (4.7 to 11.5) |
| EASI Total Score <=5: At Week 4 | 22.8 (17.6 to 28.1) |
| EASI Total Score <=5: At Week 16 | 55.1 (48.7 to 61.4) |
| EASI Total Score <=5: At Week 24 | 63.0 (56.8 to 69.1) |
| EASI Total Score <=3: At Week 2 | 3.2 (1.0 to 5.4) |
| EASI Total Score <=3: At Week 4 | 11.4 (7.4 to 15.4) |
| EASI Total Score <=3: At Week 16 | 33.7 (27.8 to 39.6) |
| EASI Total Score <=3: At Week 24 | 43.8 (37.4 to 50.1) |
The EASI is used to assess the severity and extent of AD; it is a composite index with scores ranging from 0 to 72, with higher values indicating more severe and or extensive disease. EASI 75 is defined as 75% reduction from baseline in the EASI score. EASI 90 is defined as 90% reduction from baseline in the EASI score. Percentage of participants who achieved EASI 75 and EASI 90 at each visit was reported.
| Percentage of participants | Lebrikizumab |
|---|---|
| EASI 75: At Week 2 | 7.7 (4.4 to 11.1) |
| EASI 75: At Week 4 | 21.4 (16.2 to 26.5) |
| EASI 75: At Week 16 | 58.7 (52.4 to 65.0) |
| EASI 75: At Week 24 | 63.5 (57.4 to 69.7) |
| EASI 90: At Week 2 | 1.2 (0.0 to 2.6) |
| EASI 90: At Week 4 | 5.3 (2.5 to 8.1) |
| EASI 90: At Week 16 | 23.1 (17.8 to 28.4) |
| EASI 90: At Week 24 | 34.1 (28.1 to 40.1) |
The IGA is an instrument used to globally rate the severity of the participant's AD. It is based on a 5-point scale ranging from 0 (clear), 1 (almost clear), 2 (mild), 3 (moderate) and 4 (severe), and a score is selected using descriptors that best describe the overall appearance of the lesions at a given time point. The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting (minimal, palpable induration and significant induration). Percentage of participants with an IGA Score of 0 or 1 and a reduction \>=2 points from baseline at each visit was reported.
| Percentage of participants | Lebrikizumab |
|---|---|
| At Week 2 | 4.9 (2.2 to 7.5) |
| At Week 4 | 11.0 (7.1 to 14.9) |
| At Week 16 | 32.3 (26.3 to 38.2) |
| At Week 24 | 41.3 (35.1 to 47.6) |
SCORAD is a validated clinical tool for assessing the extent and intensity of AD. There are 3 components: surface involvement, intensity part and subjective assessment. Surface involvement is assessed as proportion of involved surface area segment by segment by applying the rule of 9s. Intensity part of the SCORAD consists of 6 items: erythema, oedema, oozing/crusting, excoriation, lichenification, and dryness. Each item is graded as follows: none (0), mild (1), moderate (2), or severe (3) (for a maximum of 18 total points). Subjective assessment of itch and of sleeplessness is recorded for each symptom using a VAS, where 0 is no itch (or sleeplessness) and 10 is the worst imaginable itch (or sleeplessness), for maximum possible score of 20. The score ranges from 0 to 103, with higher values indicating a more extensive and/or severe condition. SCORAD 75 is defined as 75% reduction in SCORAD from baseline. SCORAD 90 is defined as 90% reduction in SCORAD from baseline.
| Percentage of participants | Lebrikizumab |
|---|---|
| SCORAD 75: At Week 2 | 0.1 (0.0 to 0.5) |
| SCORAD 75: At Week 4 | 2.0 (0.0 to 4.2) |
| SCORAD 75: At Week 16 | 9.1 (4.5 to 13.6) |
| SCORAD 75: At Week 24 | 20.4 (13.8 to 27.0) |
| SCORAD 90: At Week 2 | 0 (0.0 to 0.0) |
| SCORAD 90: At Week 4 | 0.6 (0.0 to 1.7) |
| SCORAD 90: At Week 16 | 0.9 (0.0 to 2.5) |
| SCORAD 90: At Week 24 | 3.4 (0.5 to 6.2) |
mTLSS combines an evaluation of hand eczema lesions severity including 6 key signs (erythema, desquamation, lichenification/hyperkeratosis, vesiculae, oedema, fissures) and the intensity of pruritus and pain. The seven features of AD of the hands (erythema, scaling, lichenification/hyperkeratosis, vesiculation, oedema, fissures, pruritus/pain) form the composite scale of mTLSS' strength and each one of them scores from (0 = none, 1 = mild, 2 = moderate, and 3 = severe). The scores are summed, extending from a base estimation of 0 (no signs or symptoms) to the most extreme of 21 (more serious disease). Percentage change from baseline was calculated as: (\[Observed or imputed value at post-baseline time point (i.e. Visit) - Observed value at Baseline\]/Observed value at Baseline) \*100.
| Percentage change | Lebrikizumab |
|---|---|
| Baseline | 9.7 ± 0.32 |
| Percent change at Week 2 | -20.6 ± 3.16 |
| Percent change at Week 4 | -37.9 ± 2.78 |
| Percent change at Week 16 | -62.1 ± 3.02 |
| Percent change at Week 24 | -66.3 ± 2.86 |
The Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity score over the past 24 hours, with 0 (No itch) to 10 (Worst itch imaginable). Assessments will be recorded by the participant using an eDiary. Percentage of participants with pruritus NRS \>=4 at baseline who achieved \>=4-Point improvement in pruritus NRS from baseline at each visit was reported
| Percentage of participants | Lebrikizumab |
|---|---|
| At Week 2 | 6.0 (2.9 to 9.1) |
| At Week 4 | 22.4 (16.8 to 27.9) |
| At Week 16 | 50.9 (43.5 to 58.3) |
| At Week 24 | 47.3 (40.0 to 54.5) |
The DLQI is a 10-item validated questionnaire completed by the participant or caregiver used to assess the impact of skin disease on the participant's QoL during the previous week. The 10 questions cover the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, and treatment. Each question is scored from 0=not at all, 1=a little, 2=a lot, and 3=very much, giving a total score ranging from 0 to 30. A high score is indicative of a poor QoL. DLQI scores indicates 0-1 (no effect on patient's life), 2-5 (small effect on patient's life), 6-10 (moderate effect on patient's life), 11-20 (very large effect on patient's life), 21-30 (extremely large effect on patient's life). Percentage of participants who achieved DLQI 0-1 at each visit was reported.
| Percentage of participants | Lebrikizumab |
|---|---|
| DLQI 0 or 1 at Week 2 | 4.4 (1.7 to 7.1) |
| DLQI 0 or 1 at Week 4 | 12.1 (7.8 to 16.4) |
| DLQI 0 or 1 at Week 16 | 29.9 (23.9 to 36.0) |
| DLQI 0 or 1 at Week 24 | 21.4 (15.7 to 27.2) |
DLQI is a 10-item validated questionnaire completed by the participant or caregiver used to assess the impact of skin disease on the participant's QoL during the previous week. The 10 questions cover the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, and treatment. Each question is scored from 0=not at all, 1=a little, 2=a lot, and 3=very much, giving a total score ranging from 0 to 30. High score is indicative of a poor QoL. Percentage of participants with DLQI \>=4 at Baseline who achieved \>=4-Point improvement in DLQI from baseline at each visit was reported.
| Percentage of participants | Lebrikizumab |
|---|---|
| At Week 2 | 55.6 (48.4 to 62.8) |
| At Week 4 | 73.0 (66.4 to 79.5) |
| At Week 16 | 84.8 (79.1 to 90.5) |
| At Week 24 | 81.4 (75.2 to 87.6) |
cDLQI is validated from adolescents younger than age of 16 years, which is based on a set of 10 questions different from those of the DLQI. The answers to the questions are generally scored on a 4-point scale from 0=not at all or question unanswered, 1=only a little, 2=quite a lot, 3=very much. cDLQI is calculated by summing the score of each question resulting in 0 to 30. Higher the score, the more impairment of the child's life is experienced. Percentage of participants who achieved cDLQI 0-1 at each visit was reported.
| Percentage of participants | Lebrikizumab |
|---|---|
| cDLQI 0 or 1 at Week 2 | 0.3 (0.0 to 5.0) |
| cDLQI 0 or 1 at Week 4 | 4.0 (0.0 to 20.2) |
| cDLQI 0 or 1 at Week 16 | 11.0 (0.0 to 30.3) |
| cDLQI 0 or 1 at Week 24 | 30.7 (3.5 to 57.9) |
cDLQI is validated from adolescents younger than age of 16 years, which is based on a set of 10 questions different from those of the DLQI. The answers to the questions are generally scored on a 4-point scale from 0=not at all or question unanswered, 1=only a little, 2=quite a lot, 3=very much. cDLQI is calculated by summing the score of each question resulting in 0 to 30. Higher the score, the more impairment of the child's life is experienced. Percentage of participants with cDLQI \>=6 at baseline who achieved \>=6-Point improvement in cDLQI from baseline at each visit was reported.
| Percentage of participants | Lebrikizumab |
|---|---|
| At Week 2 | 44.4 (12.0 to 76.9) |
| At Week 4 | 64.0 (31.3 to 96.7) |
| At Week 16 | 52.4 (18.4 to 86.5) |
| At Week 24 | 66.2 (35.0 to 97.4) |
Sleep loss will be assessed by all participants using a patient-related outcome (PRO) instrument. Participants (and if applicable, with help of parents/caregiver if required) will rate their sleep on a 5-point Likert scale (with scores ranging from 0 \[not at all\] to 4 \[unable to sleep at all\]). Assessments will be recorded by the participant using an eDiary.The baseline Sleep-Loss Scale score will be determined based on the average of daily Sleep-Loss Scale scores during the 7 days immediately before the Day 1 or Baseline visit. Percentage of participants with a Sleep-Loss scale of \>=2 points at baseline who achieved at least 2-point reduction from baseline at each visit was reported.
| Percentage of participants | Lebrikizumab |
|---|---|
| At Week 2 | 2.8 (0.0 to 6.0) |
| At Week 4 | 26.1 (17.6 to 34.5) |
| At Week 16 | 33.9 (23.9 to 43.8) |
| At Week 24 | 36.2 (26.8 to 45.5) |
The POEM is a 7-item, validated questionnaire completed by the participant (and, if applicable, with help of parents/caregiver if required) to assess disease symptoms. Participants are asked to respond to questions on skin dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping. All answers carry equal weight, with a total possible score ranging from 0 to 28 (answers scored as: No days = 0; 1-2 days = 1; 3-4 days = 2; 5-6 days = 3; every day = 4. A high score is indicative of a poor quality of life. POEM responses are captured weekly using an eDiary. Percentage of participants with POEM \>=4 at baseline who achieved \>=4-Point improvement in POEM from baseline at each visit was reported.
| Percentage of participants | Lebrikizumab |
|---|---|
| At Week 2 | 46.1 (39.0 to 53.3) |
| At Week 4 | 79.8 (74.0 to 85.6) |
| At Week 16 | 89.7 (85.1 to 94.3) |
| At Week 24 | 87.9 (82.5 to 93.2) |
TEAEs are undesirable events that first occurred or worsened in severity after the date of first IMP injection in the study, and on or prior to the date of the last visit within the treatment period. An SAE are AE, which falls into any of the following categories: death, is life-threatening, requires in-patient hospitalisation or prolongs existing hospitalisation, persistent or significant disability or incapacity, congenital anomaly or birth defect, or any other medically important event that may jeopardise the participant or may require intervention to prevent one of the other above outcomes. Related TEAEs includes events considered related or possibly related to study treatment by the Investigator. The following treatment-emergent AEs are being designated as AESIs: conjunctivitis, herpes simplex or zoster infection and parasitic infections.
| Participants | Lebrikizumab |
|---|---|
| Participants with at least one TEAE | 204 |
| Participants with at least one SAE | 7 |
| Participants with at least one related TEAE | 131 |
| Participants with at least one TEAE leading to treatment discontinuation | 6 |
| Participants with at least one TEAESI | 70 |
Collected over Baseline up to follow-up (Week 28). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lebrikizumab | 0/260 (0%) | 7/260 (2.7%) | 127/260 (48.8%) |
| Event | Lebrikizumab |
|---|---|
| Dermatitis atopicSkin and subcutaneous tissue disorders | 1/260 |
| Erythrodermic atopic dermatitisSkin and subcutaneous tissue disorders | 1/260 |
| Mitral valve prolapseCardiac disorders | 1/260 |
| Anal fistulaGastrointestinal disorders | 1/260 |
| Chest discomfortGeneral disorders | 1/260 |
| Herpes simplexInfections and infestations | 1/260 |
| Staphylococcal skin infectionInfections and infestations | 1/260 |
| Tendon ruptureInjury, poisoning and procedural complications | 1/260 |
| EndometriosisReproductive system and breast disorders | 1/260 |
| Event | Lebrikizumab |
|---|---|
| NasopharyngitisInfections and infestations | 66/260 |
| ConjunctivitisInfections and infestations | 46/260 |
| Dermatitis atopicSkin and subcutaneous tissue disorders | 30/260 |
| HeadacheNervous system disorders | 19/260 |
| Dry eyeEye disorders | 18/260 |
Full Analysis Set (FAS) included all enrolled participants.
| Age, Continuous(years) | Lebrikizumab |
|---|---|
| Mean | 32.9 ± 14.10 |
| Sex: Female, Male(Participants) | Lebrikizumab |
|---|---|
| Female | 106 |
| Male | 154 |
| Ethnicity (NIH/OMB)(Participants) | Lebrikizumab |
|---|---|
| Hispanic or Latino | 2 |
| Not Hispanic or Latino | 239 |
| Unknown or Not Reported | 19 |
| Race (NIH/OMB)(Participants) | Lebrikizumab |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 16 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 1 |
| White | 230 |
| More than one race | 11 |
| Unknown or Not Reported | 2 |
| Region of Enrollment(participants) | Lebrikizumab |
|---|---|
| Netherlands | 8 |
| United Kingdom | 34 |
| Germany | 218 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2023 to primary completion in Jun 2025, 19 months.
Results were first posted in Jul 2026, 1 year after primary completion.
Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 19 months is close to that.
Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lebrikizumab